Skip to content
GENIUS-CHD
GENIUS-CHD
Genetics of Subsequent Coronary Heart Disease
  • GENIUS-CHD
  • About
    • What is GENIUS-CHD?
    • Background & Rationale
  • Member Cohorts
  • Organisation
    • Scientific Steering Committee
    • Operational Committee
    • Project Specific Working Groups
  • Join Us
  • News
  • Documents
  • Contact

Contact Us

For all general enquiries, please contact us by email at:  genius.consortium@gmail.com

If you have any specific or scientific enquiries, please contact:

 

Dr. Riyaz Patel (UCL)

Email: riyaz.patel@ucl.ac.uk

 

Or

 

Prof. Folkert Asselbergs (UMCU)

Email: f.w.asselbergs@umcutrecht.nl

 

Contact us via email: genius.consortium@gmail.com

RSS Latest Articles on Subsequent CAD Risk Research

  • Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial April 11, 2021
    CONCLUSIONS: Like HF hospitalizations, worsening HF events treated in the ambulatory setting are prognostically important in HFpEF. Inclusion of these events in the composite primary endpoint underscores the benefit of sacubitril/valsartan compared with valsartan in PARAGON-HF. (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
Copyright © 2021 GENIUS-CHD — Stout WordPress theme by GoDaddy